Bio-Thera Solutions, Ltd. (SHA:688177)
20.21
-0.14 (-0.69%)
At close: May 12, 2026
Bio-Thera Solutions Revenue
Bio-Thera Solutions had revenue of 251.59M CNY in the quarter ending March 31, 2026, with 21.80% growth. This brings the company's revenue in the last twelve months to 980.25M, up 24.38% year-over-year. In the year 2025, Bio-Thera Solutions had annual revenue of 935.22M with 25.84% growth.
Revenue (ttm)
980.25M
Revenue Growth
+24.38%
P/S Ratio
8.60
Revenue / Employee
783.57K
Employees
1,266
Market Cap
8.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 935.22M | 192.05M | 25.84% |
| Dec 31, 2024 | 743.17M | 38.37M | 5.44% |
| Dec 31, 2023 | 704.79M | 249.66M | 54.86% |
| Dec 31, 2022 | 455.13M | -381.45M | -45.60% |
| Dec 31, 2021 | 836.58M | 653.72M | 357.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.84B |
| Aurisco Pharmaceutical | 1.68B |
| Nanjing Vazyme Biotech | 1.41B |
| Shanghai Medicilon | 1.26B |
| Chengdu Kanghua Biological Products | 1.20B |
| Acrobiosystems | 887.21M |
| GemPharmatech | 830.61M |